Document:

Exhibit
10.9

 

AMENDMENT
TO

COMMERCIAL
PROMISSORY NOTE

 

THIS
AMENDMENT, dated this 18th day of June 2019, by and between PEN BRANDS LLC, successor by merger to Nanofilm, Ltd.,
an Ohio limited liability company, whose principal office is located at 101 I l Sweet Valley Drive, Valley View, Ohio, 44125 (hereinafter
referred to as “Borrower”), and KEYBANK NATIONAL ASSOCIATION, a national banking corporation whose principal office
is located at 127 Public Square, Cleveland, Ohio, 441 14 (hereinafter referred to as “Bank”);

 

WITNESSETH:

 

WHEREAS,
Bank extended to Nanofilm, Ltd., n/k/a PEN Brands LLC, a certain commercial line of credit on or about February 10th,
2015 in the original principal amount of up to Three Hundred Seventy-three “Thousand and 00/100 Dollars ($373,000.00 - the
“Loan”) as evidenced by the commercial Promissory’ Note executed on, dated and delivered to Bank by Borrower
on February 10th, 2015, in the original principal amount of Three Hundred Seventy-three Thousand and 00/100 Dollars
($373,000.00) (hereinafter referred to as “Note”, a copy of which is attached and incorporated herein as Exhibit “A”);
and

 

WHEREAS,
Borrower is presently indebted to Bank, as to said Loan, in the principal amount of $132,665.57 (as of March 19th,
2019), evidenced by the aforesaid Note; and

 

WHEREAS,
Borrower has become delinquent and has defaulted on the subject Loan and Note and, consequently, has requested that Bank re-amortize
the balance of the Loan and extend the maturity thereof; and

 

WHEREAS,
in furtherance of Borrower’s request, Bank and Borrower have agreed to amend the Note to: (i) extend its maturity; (ii)
increase the applicable non-default interest rate thereof; and (iii) modify (the payments required thereunder,

 

NOW
THEREFORE, in consideration of the premises contained herein and for other good and valuable consideration, the receipt of which
is hereby acknowledged, Borrower and Bank hereby mutually agree to amend and modify the aforementioned Note as follows, to wit:

 

1.
Effective with the execution hereof, and subject to Bank’s right to accelerate consistent with the terms of the Note,
the maturity date under the Note shall be extended twenty-two (22) months from June 10th, 2020 to April
10th, 2022 (the “Maturity” or “Maturity Date”), on which date the entire balance
outstanding, if any, including all interest that has accrued, shall be paid in full to Bank by Borrower.

 

2.
Effective with the execution hereof, the applicable non-default interest rate under the Note shall be changed from the fixed
rate of four and thirty-five hundredths of one percent (4.35%) per annum to the fixed rate of six and twenty-nine hundredths
of one percent (6.29%) per annum.

 

3.
Effective with the execution hereof the Note is hereby amended to reflect that the Loan is to be re-amortized over
a term of 36 months with payments heretofore required under the Note being hereby modified from principal and
interest payments in the amount of Six Thousand One Hundred Ninety-eight and 37/100 Dollars ($6,198.37) each to
principal and interest payments in the amount of Four Thousand Fifty-three and 40/100

 

    	 	 	 

    	 

    

 

Dollars
($4,053.40) each. Said payments shall be due on the 10th day of each consecutive month beginning May 10th,
2019 and continuing thereafter to Maturity, with one final payment due at Maturity, whether by acceleration or by lapse of time,
in an amount equal to the principal balance then outstanding, plus all accrued and unpaid interest. Moreover, all outstanding
interest and late fees, together with costs and expenses incurred therefor by Bank shall be paid by Borrower at the time of the
execution hereof.

 

4.
Borrower ratifies and confirms that the Note is secured by Borrower’s equipment, identified as a reconditioned Double
Fold F/F/S Machine, Model V12M, Serial #2205-1234, including all accessions, attachments, accessories, replacements of said
collateral, and all records accounts, general intangibles, instruments, rents, monies, payments, proceeds, and all other
rights relating thereto.

 

5.
The Borrower hereby represents and warrants to Bank that (a) Borrower has the legal authority to execute and deliver this
Amendment; (b) the officers executing this Amendment have been duly authorized to execute and deliver same and bind the
Borrower with respect to the provisions hereof; (c) the execution and delivery hereof by the Borrower and the performance and
observance by Borrower of the provisions hereof do not violate or conflict with the organizational agreements of the Borrower
or any law applicable to Borrower nor would result in a breach of any provisions of or constitute a default under
another agreement, instrument or document bearing upon or enforceable against the Borrower; and (d) this Amendment
constitutes a valid and binding obligation upon Borrower in every respect.

 

6.
In consideration of this Amendment, Borrower hereby fully releases and discharges the Bank and its shareholders, directors,
officers, employees, attorneys, parent, affiliates and subsidiaries from any and all claims, demands, liability, and causes
of action whatsoever, now known or unknown, arising out of or in any way related to the extension or administration of the
Loan, the Note and all security interests related thereto.

 

FURTHER,
it is hereby understood and agreed that this Note Amendment shall be construed as a revision of the aforementioned
Note only, and not a novation; and except as herein provided all the terms and conditions of said Note shall remain in full force
and effect according to the original terms, conditions and provisions thereof, as heretofore amended and as subsequently modified
or amended by consent and agreement of all the parties, except that the changes set forth herein shall supersede all prior amendments
to the Note, if any.

 

The undersigned Borrower authorizes any attorney-at-law at any time or times after the maturity hereof to appear in
any state or federal court of record in the United States of America, to waive the issuance and service of process, to admit the
maturity of this note and the nonpayment thereof when due, to confess judgment against the undersigned Borrower in favor of the
holder of this note for the amount then appearing due, together with interest and costs of suit, and thereupon to release all
errors and to waive all rights of appeal and stay of execution. The foregoing warrant of’ attorney shall survive any judgment,
and if any judgment be vacated for any reason, the holder hereof nevertheless may thereafter use the foregoing warrant of attorney
to obtain an additional judgment or judgments against the undersigned Borrower. The undersigned Borrower agrees that the holder’s
attorney may confess judgment pursuant to the foregoing warrant of attorney. The undersigned Borrower further agrees that the
attorney confessing judgment pursuant to the foregoing warrant of attorney may receive a legal fee or other compensation from
the holder.

 

IN
WITNESS WHEREOF, Borrower and Bank have caused this instrument to be executed on the 18th day of June 2019.

 

WARNING
- BY SIGNING THIS PAPER YOU GIVE UP YOUR RIGHT TO NOTICE AND COURT TRIAL. IF YOU DO NOT PAY ON TIME A COURT JUDGMENT MAY BE TAKEN
AGAINST YOU WITHOUT YOUR PRIOR KNOWLEDGE AND THE POWERS OF A COURT CAN BE USED TO COLLECT FROM YOU REGARDLESS OF ANY CLAIMS YOU
MAY HAVE AGAINST THE CREDITOR WHETHER FOR RETURNED GOODS FAULTY GOODS FAILURE ON HIS PART TO COMPLY
WITH THE AGREEMEN’I’ OR ANY OTHER CAUSE.

 

	BANK
    :	 	KEYBANK
    NATIONAL ASSOCIATION, a national banking corporation
	 	 	 	 	 
	 	 	 	BORROWER:
	 	 	 	 	 
	By:	/s/
    Charles Button	 	 	 
	 	Charles
    Button, Assistant Vice President 	 	 	 
	 	 	 	 	 
	 	 	 	PEN
    BRANDS LLC, successor by merger to
	 	 	 	Nanofilm,
    Ltd., an Ohio limited liability company
	 	 	 	 	 
	 	 	 	By:	/s/
    Tom J Berman
	 	 	 	 	Tom
    J. Berman, Manager, President and Chief Executive Officer
	 	 	 	 	 
	 	 	 	By:	/s/
    Jeanne M Rickert
	 	 	 	 	Jeanne
    M. Rickert, SecretaryExhibit

                                 Exhibit 10.5
FIBROCELL SCIENCE, INC. 
405 Eagleview Boulevard
Exton, Pennsylvania 19341

September 12, 2019
CASTLE CREEK PHARMACEUTICAL HOLDINGS, INC.
CASTLE CREEK PHARMACEUTICALS, LLC

Re:    Agreement and Plan of Merger

Ladies and Gentlemen:
Reference is hereby made to the Agreement and Plan of Merger, executed contemporaneously herewith (the “Merger Agreement”), by and among Fibrocell Science, Inc., a Delaware corporation (the “Company”), Castle Creek Pharmaceutical Holdings, Inc., a Delaware corporation (“Parent”), and Castle Creek Merger Corp., a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”).  Pursuant to the Merger Agreement, and on the terms and conditions set forth in the Merger Agreement, Merger Sub will merge with and into the Company (the “Merger”), with the Company surviving the Merger as a wholly owned subsidiary of Parent.  In consideration of the parties’ execution of the Merger Agreement, and in consideration of the mutual promises and agreements herein and therein made, the undersigned parties agree as follows:    
1.Advancement of Funds under License Agreement.  If the Closing (as defined in the Merger Agreement) of the Merger has not occurred on or before the date of the Payments Advance, then Parent shall, upon the Company’s written request made at any time on or after January 1, 2020 and prior to January 15, 2020, advance to the Company no later than January 31, 2020 funds in an amount not to exceed $3 million (the “Payments Advance”), representing certain future payments  payable to the Company (which, for the avoidance of doubt, does not include any payments to be made by CCP (as defined below) for services previously performed by the Company) pursuant to that certain Co-Development and License Agreement (the “CCP Sub-License”), dated April 12, 2019, by and between Castle Creek Pharmaceuticals, LLC, a Delaware limited liability company (“CCP”) and the Company; provided that:  (a) payment by Parent of the Payments Advance is contingent upon (i) receipt of all consents required by the terms of any of the Company’s material agreements, including the Company’s Convertible Promissory Notes due September 7, 2026 and (ii) the Merger Agreement is in full force and effect on the date of the Payments Advance; and (b) if for any reason the Closing does not occur and the Merger Agreement is terminated, the amount of such Payments Advance will be offset against the future payment obligations of CCP under the CCP Sub-License. 
2.    No Conflicts. The execution, delivery and performance of this letter agreement by the Company, do not and will not (i) violate any laws (including securities laws) applicable to the Company, or (ii) subject to receipt of all consents required by the terms of any of the Company’s 

     
  
  

 

material agreements, including the Company’s Convertible Promissory Notes due September 7, 2026, result in a material breach or default (or event which with the giving of note or lapse of time, or both, would result in a default) under, or violate or conflict with, any of the organizational documents or any contract, agreement or obligation of the Company, or under any order, writ, judgment, injunction, decree, determination or award of any governmental entity, in each case applicable to the Company or the Company’s properties.
3.    Governing Law.  This letter agreement shall be governed by and construed and enforced in accordance with the laws of the State of Delaware, without regard to principles of conflicts of law.
4.    Miscellaneous.  This letter agreement may be executed in any number of counterparts, each of which shall be deemed an original and all of which taken together shall constitute one and the same instrument. This letter agreement supplements the Merger Agreement, and in the event of a conflict between the provisions of this letter agreement and the Merger Agreement, the provisions of this letter agreement shall control. Notwithstanding anything to the contrary contained in the Merger Agreement or this letter agreement, this letter agreement shall be deemed executed contemporaneously with the Merger Agreement and will survive any amendment or restatement of the Merger Agreement.  Section 19.6 and Section 19.7 of the CCP Sub-License are incorporated herein by reference mutatis mutandis. 

[The remainder of this page is intentionally left blank.]

    
If the foregoing meets with your approval, kindly countersign this letter agreement below to indicate your acceptance and agreement to its terms.
	
	
	Very truly yours,
FIBROCELL SCIENCE, INC.

	   By:   /s/ John Maslowski    
Name: John Maslowski 
Title: President and Chief Executive Officer

Agreed and accepted 
as of the date first above written:

CASTLE CREEK PHARMACEUTICAL HOLDINGS, INC.

		
	By:
	/s/ Greg Wujek         
Name:    Greg Wujek 
Title:    Chief Executive Officer 

CASTLE CREEK PHARMACEUTICALS, LLC

		
	By:
	/s/ Greg Wujek         
Name:    Greg Wujek 
Title:     Chief Executive Officer

2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00302-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00302-of-00352.parquet"}]]